Saudi Arabia In-vitro Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Saudi Arabia In-vitro Diagnostics Market Trends and Insights

Escalating Chronic Disease Prevalence

Saudi Arabia’s diabetic population is projected to grow from 2.69 million in 2020 to 4.21 million by 2030, boosting demand for HbA1c, lipid, and tumor marker panels. King Faisal Specialist Hospital’s AI-driven hematology lab launched in 2024 processes 9,000 flow tests annually, illustrating nationwide upgrades that support precision hematology^{[1]King Faisal Specialist Hospital & Research Centre, “Advanced Hematology Diagnostics Lab Launch,” kfshrc.edu.sa}. The Ayenati network now links 1,194 reference labs and has logged 5.3 million samples, creating a national data backbone for population screening. ISO 15189 accreditation is becoming a gatekeeper for public tenders, concentrating volumes within labs that maintain rigorous quality systems.

Growing Government Healthcare Expenditure and Vision 2030 Investments

Health-sector budgets rose to SAR 214 billion (USD 57.1 billion) in 2024 and are slated for SAR 260 billion (USD 69.3 billion) by 2026, funneling funds into lab modernization, digital pathology, and telemedicine nodes. Privatization plans covering 290 public hospitals will fragment procurement and widen access for specialty-test vendors. Lifera Omics, a November 2023 joint venture with CENTOGENE, positions the Kingdom to localize multiomic testing, reducing outbound sample flows. NPHIES now covers 31 million insured residents, mandating real-time claims adjudication that rewards digitized labs.

Rapid Expansion of Private Healthcare Infrastructure

Al Borg Diagnostics serves 15,000 daily customers and opened two of the region’s largest reference labs in 2023, driving economies of scale in molecular testing. BD and QIAGEN secured regional headquarters licenses in Riyadh during 2023-2024, enabling co-developed clinical guidelines and shortening technology rollouts. Private operators’ flexible capital structures accelerate adoption of total lab automation, positioning them to meet precision-medicine demand ahead of public counterparts.

Rising Demand for Personalized and Genomic Diagnostics

The Saudi Genome Program has sequenced more than 10,000 genomes, shifting focus from research to routine clinical decision-making. Lifera Omics’ Riyadh facility integrates phenomics, genomics, and proteomics, slashing oncology-panel turnaround from weeks to days. QIAGEN’s localized data center provides on-shore bioinformatics, addressing data-sovereignty concerns and ensuring faster variant interpretation. AI-enabled multiparametric flow cytometry at King Faisal Specialist Hospital underscores the market’s pivot toward precision hematology.

Limited Reimbursement for Advanced Molecular Assays

The Council of Cooperative Health Insurance reimburses insulin pumps under strict criteria but has not published guidelines for next-generation sequencing or liquid-biopsy assays, leaving most advanced molecular tests self-pay^{[2]Saudi National Diabetes Center, “Reimbursement Guidelines and Device Safety Alerts,” sndc.sa}. Fragmented private-payer policies force suppliers into piecemeal negotiations, inflating administrative costs and slowing adoption. Penetration of insulin pumps among type 1 diabetics remains below 3%, underscoring how eligibility rules can suppress device uptake even when clinical value is clear. Absent a national medical-device formulary, coverage decisions vary widely, perpetuating regional inequities in access to precision diagnostics.

Stringent Regulatory Approval Processes

The Saudi Food and Drug Authority’s four-tier IVD risk classification demands pre-market scientific evaluation and post-market surveillance, driving approval timelines for Class C and D devices past 12 months^{[3]Saudi Food and Drug Authority, “IVD Device Classification Framework,” sfda.gov.sa}. Local bridging studies add complexity for rare-disease panels with limited Saudi cohorts. NUPCO tenders layer additional technical and delivery requirements, favoring incumbents with proven local supply chains. While vigilance safeguards patient safety—the National Center for Medical Device Reporting issued 253 safety alerts between 2021-2024—lengthy approvals can let competitors leapfrog first movers with newer technologies.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Test Type: Molecular Diagnostics Gains on Clinical Chemistry’s Volume Base

Clinical chemistry commanded 35.1% revenue in 2025 on the strength of high-volume liver-function and lipid panels. Despite this, the Saudi Arabia in-vitro diagnostics market size for molecular assays is projected to expand at a 5.33% CAGR through 2031, the fastest among test types. Uptake is fueled by syndromic infectious-disease panels and oncology profilers required for targeted therapies. King Faisal’s automated flow cytometry track exemplifies a nationwide pivot toward AI-assisted hematology that reduces manual microscopy and enriches immunophenotyping depth. Immuno-diagnostics remains essential but faces margin compression under NUPCO’s bulk-purchase pricing caps. Hematology platforms now bundle digital image analysis, optimizing throughput amid staffing shortages.

Workflow efficiency differentiates suppliers. Beckman Coulter’s DxC 700 AU analyzer cut processing steps by 30%, aligning with labs’ need to handle rising sample loads without headcount growth. National interoperability mandates through the Ayenati network further accelerate retirement of legacy instruments lacking digital connectivity. Overall, molecular diagnostics’ high growth rate will rebalance the Saudi Arabia in-vitro diagnostics market toward precision tests while preserving clinical chemistry’s foundational role.

By Product: Reagents & Kits Dominate, Instruments Enter an Upgrade Cycle

Reagents and kits held 68.12% revenue in 2025, reflecting consumable annuity economics that lock customers into proprietary chemistries over instrument lifespans. Yet instruments are expected to record a 5.66% CAGR by 2031 as labs modernize under Vision 2030. Al Borg’s twin reference labs required next-generation sequencers, high-throughput chemistry tracks, and digital pathology scanners, all of which create durable reagent pull-through. The Saudi Arabia in-vitro diagnostics market share for high-value specialty reagents—flow cytometry cocktails, liquid-biopsy kits—will outpace commoditized routine chemistries, buffering suppliers against pricing pressure.

Suppliers now bundle predictive maintenance and remote diagnostics; Beckman Coulter’s “3 & 60” concept allows part changes in three steps within 60 seconds, minimizing downtime where field engineers are scarce. Privatization of 290 hospitals will transfer procurement authority from centralized NUPCO tenders to emerging group-purchasing organizations, favoring vendors offering flexible financing and localized service.

By Usability: Disposable Devices Prevail, Re-Usables Ride Automation

Disposable devices captured 71.32% of 2025 revenue as infection-control protocols and single-use cartridges became entrenched during COVID-19. Conversely, reusable analyzers, tracks, and sequencing platforms are projected to grow at 5.87% through 2031 as hospitals chase economies of scale. King Faisal’s automated hematology track shows how high-throughput reusable systems can absorb rising volumes without proportional staffing. Home-care adoption of connected CGMs and insulin pumps like Omnipod 5 underscores a parallel surge in disposables that feed longitudinal data into care pathways while shifting HbA1c testing out of labs.

Compliance oversight is intense: the Saudi Food and Drug Authority had cleared 12 CGMs by September 2024 and investigated 427 home-use device incidents since 2021, issuing 253 safety alerts. Reusable platforms increasingly integrate data analytics; BD’s safety memorandum with 500 hospitals embeds software that feeds specimen-tracking metrics into hospital systems. This dual-track evolution will persist, with disposables dominating primary care and reusables anchoring high-volume centers.

By Application: Infectious Disease Still Leads, Oncology Rises Fastest

Infectious disease testing held a 42.65% revenue share in 2025, underpinned by residual COVID-19 capacity and endemic TB, hepatitis, and meningitis. QIAGEN’s QIAstat-Dx platform for national meningitis elimination and QuantiFERON-TB Gold Plus for latent TB screening embeds molecular tests into public-health protocols. The Saudi Arabia in-vitro diagnostics market size for oncology panels, however, is forecast to grow at 6.12% CAGR, the fastest among applications, propelled by rising cancer incidence and localized multiomic testing at Lifera Omics. Diabetes testing retains high volumes although CGMs dampen lab HbA1c demand.

Cardiology assays for troponins and BNP are migrating to emergency-department point-of-care instruments, shortening decision cycles for acute-coronary-syndrome management. King Faisal’s AI-enabled hematology services illustrate growing demand for minimal residual disease monitoring in hematologic malignancies. Government HPV molecular screening agreements further entrench oncology testing in national preventive frameworks.

By End User: Labs Dominate, Home & POC Settings Surge

Diagnostic laboratories captured 47.87% of 2025 revenue, benefiting from centralized procurement and reference-lab consolidation. However, home-care and point-of-care environments will expand at a 6.54% CAGR, outpacing all other segments. The Omnipod 5 automated insulin-delivery system, launched in 2026, exemplifies decentralized devices generating clinically actionable data outside traditional labs. Hospitals now embed point-of-care platforms for troponins and blood gases, diverting urgent tests away from central labs.

Ayenati’s network connectivity lets smaller facilities outsource esoteric assays while retaining patient relationships, raising the Saudi Arabia in-vitro diagnostics market’s digital maturity. NPHIES real-time adjudication incentivizes electronic ordering and result reporting, favoring organizations with robust IT interfaces. BD’s partnership with the Saudi Patient Safety Center extends specimen-management best practices across 500 hospitals, demonstrating how enterprise-wide initiatives can transform end-user requirements.

Regulatory Landscape

In Saudi Arabia, in-vitro diagnostics (IVDs) are regulated by the Saudi Food and Drug Authority (SFDA) under the Medical Devices Law (Royal Decree No. M/54) and associated implementing requirements. The SFDA uses a four-tier, risk-based IVD classification (Classes A to D) and requires Medical Devices Marketing Authorization (MDMA) prior to placing products on the market, with establishment licensing obligations for parties importing, marketing, or distributing devices (including local Authorized Representative requirements for foreign manufacturers).

The framework is also tightening for specialized and higher-complexity testing. In 2025, the SFDA issued specific guidance for in-house (lab-developed) IVDs (MDS-G022) and for companion diagnostics (MDS-G026). These updates reinforce expectations around clinical performance evidence and alignment to clinical performance study requirements (MDS-REQ2), including recognized standards such as ISO 20916. For oncology and precision-medicine assays, the guidance raises the compliance bar while clarifying the pathways labs and suppliers use to expand test menus beyond routine chemistry and immunoassays.

Value Chain Analysis

Saudi Arabia's IVD value chain is led by multinational manufacturers supplying instruments, reagents, and consumables into a market that is import-reliant, then executed locally through authorized representatives and distributors that support registration, warehousing, installation, field service, and applications training. Public-sector demand is shaped by centralized procurement and logistics through NUPCO, while large reference-lab operators and tertiary hospitals drive high-throughput instrument placements that pull through proprietary reagents and specialty kits.

Upstream localization is expanding from distribution into manufacturing and on-shore capability buildout, aligned with Vision 2030 resilience priorities and procurement preferences. MODON's approval for CoMira Diagnostics (a Co-Diagnostics and Arabian Eagle Manufacturing joint venture) to establish a molecular diagnostics manufacturing facility in Sudair Industrial City is a recent example, signaling new in-country production nodes for PCR platforms. Alongside that, the market's service layer is becoming more IT- and quality-system intensive as national interoperability programs (including Ayenati connectivity) and payer digitization (including NPHIES) increase requirements for middleware integration, traceability, and standardized reporting across lab networks.

Market Opportunities and Future Outlook

Localization of IVD manufacturing and supply continuity is emerging as a clear whitespace, supported by industrial-zone enablement and specific company actions. MODON's April 2026 approval for CoMira Diagnostics to establish a molecular diagnostics manufacturing facility in Sudair Industrial City highlights a pathway for PCR and molecular-test suppliers to compete on lead times, local content, and tender readiness, not only imported availability. Sysmex's signing of an MoU to establish a diagnostic reagent factory in Saudi Arabia also points to reagent localization opportunities, which can reduce cold-chain and availability risks that affect high-volume lab operations.

Higher-complexity testing and hospital lab modernization create room for commercialization where suppliers can pair advanced platforms with compliant evidence packages and integration support. SFDA's 2025 guidance on in-house IVDs (MDS-G022) and companion diagnostics (MDS-G026) provides clearer regulatory framing for LDT governance and CDx-linked oncology workflows, encouraging structured adoption in accredited labs rather than informal test development. This aligns with Saudi Arabia's precision-medicine infrastructure, including the Saudi Genome Program and local multiomics capacity such as Lifera Omics, creating openings for on-shore bioinformatics, workflow automation, and clinically validated test menus that fit national data-sovereignty and quality requirements.